Insight Molecular Diagnostics (IMDX) Preferred Stock Liabilities (2022 - 2024)

Insight Molecular Diagnostics has reported Preferred Stock Liabilities for 3 years, with the latest figure at $5.3 million in Q1 2024.

• Quarterly Preferred Stock Liabilities fell 3.62% year-over-year to $5.3 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $5.3 million (down 3.62% YoY) and the FY2023 annual result came in at $5.1 million, down 3.32% from the prior year.
• Preferred Stock Liabilities advanced to $5.3 million in Q1 2024 per IMDX's latest filing, from $5.1 million in the prior quarter.
• Over five years, Preferred Stock Liabilities peaked at $5.5 million in Q1 2023 and troughed at $4.7 million in Q2 2023.
• A 3-year average of $5.1 million and a median of $5.1 million in 2022 frame the typical range for Preferred Stock Liabilities.
• The sharpest annual moves came in 2023 and 2024: Preferred Stock Liabilities declined 2.66% in 2023, then declined 3.62% in 2024.
• Over 3 years, Preferred Stock Liabilities stood at $5.3 million in 2022, then fell by 3.32% to $5.1 million in 2023, then increased by 4.02% to $5.3 million in 2024.
• According to Business Quant data, Preferred Stock Liabilities over the past three periods registered $5.3 million, $5.1 million, and $4.9 million for Q1 2024, Q4 2023, and Q3 2023 respectively.